glp-1 and pancreas GLP-1–Based Therapies: The Dilemma of Uncertainty GLP-1 receptor biology: structure, signaling,

tirzepatide is a dual agonist (GIP/GLP-1) Peak weight loss : Retatrutide showed 28.7% at 68 weeks (Phase 3 TRIUMPH-4) and 24.2% at 48 weeks (Phase 2) vs tirzepatide 20.9% (Phase 3) Liver fat : Retatrutide's glucagon agonism provides pronounced hepatic fat reduction (up to 82%) Regulatory status : Tirzepatide is FDA-approved

Primary Research References The core peer-reviewed publications underlying current Retatrutide research: Jastreboff AM et al

Remarkably, data even losing 5% of body weight 22 can improve heart health metricssuch as triglycerides, total cholesterol, and low-density lipoprotein (LDL) cholesterolthereby reducing heart disease risk

You may be experiencing a hormonal imbalance if youve noticed symptoms such as unexplained weight gain, chronic fatigue, low libido, poor sleep, mood swings, brain fog, or difficulty concentrating